Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPG-818 in Systemic Lupus Erythematosus
NCT04643067Phase 2Completed
- Sponsor
- Kangpu Biopharmaceuticals
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of epaldeudomide in systemic lupus erythematosus (SLE), sponsored by Kangpu Biopharmaceuticals. Started Jun 2021; status: completed.
02
Drugs
epaldeudomide
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04643067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643067.